Hyperhomocysteinemia and MTHFR C677T and A1298C polymorphisms are associated with chronic allograft nephropathy in renal transplant recipients

dc.creatorPavarino-Bertelli, EC
dc.creatorde Alvarenga, MPS
dc.creatorGoloni-Bertollo, EM
dc.creatorBaptista, MASF
dc.creatorHaddad, R
dc.creatorHoerh, NF
dc.creatorEberlin, MN
dc.creatorAbbud, M
dc.date2004
dc.dateDEC
dc.date2014-11-14T05:47:41Z
dc.date2015-11-26T16:04:38Z
dc.date2014-11-14T05:47:41Z
dc.date2015-11-26T16:04:38Z
dc.date.accessioned2018-03-28T22:53:44Z
dc.date.available2018-03-28T22:53:44Z
dc.identifierTransplantation Proceedings. Elsevier Science Inc, v. 36, n. 10, n. 2979, n. 2981, 2004.
dc.identifier0041-1345
dc.identifierWOS:000226765800024
dc.identifier10.1016/j.transproceed.2004.12.002
dc.identifierhttp://www.repositorio.unicamp.br/jspui/handle/REPOSIP/69057
dc.identifierhttp://www.repositorio.unicamp.br/handle/REPOSIP/69057
dc.identifierhttp://repositorio.unicamp.br/jspui/handle/REPOSIP/69057
dc.identifier.urihttp://repositorioslatinoamericanos.uchile.cl/handle/2250/1265534
dc.descriptionHyperhomocysteine has been reported to be an important risk factor for the development of atherosclerosis. Identification of risk factors, such as hyperhomocysteinemia, is crucial for a better understanding of the events that lead to degenerative processes in the vascular system and for a correct understanding of the potential role of methylene-tetrahydrofolate reductase enzymes (MTHFR) to help in the treatment of vascular disease observed in chronic allograft nephropathy (CAN). In this study we analyzed the plasma homocysteine concentrations and MTHFR C677T and A1298C polymorphism frequencies among 110 renal transplant recipients (53 with CAN and 57 with normal renal function). All recipients had undergone renal transplantation at least 12 months prior to this investigation to establish a possible correlation with the posttransplant outcome. Plasma homocysteine concentrations were measured by liquid chromatography-tandem mass spectrometry and MTHFR polymorphisms were investigated by the PCR-RFLP technique. The results demonstrated that in renal transplant recipients, hyperhomocysteinemia in addition to the presence of the allelic variants for both MTHFR polymorphisms (677T/1298C) might play a role as an additional risk factor for CAN. We understand that analysis of these polymorphisms might have a role in the CAN process. Therefore, studies to evaluate their presence in renal transplant patients may be extremely useful to individualize immunosuppressive protocols to inhibit or retard the progression of CAN.
dc.description36
dc.description10
dc.description2979
dc.description2981
dc.languageen
dc.publisherElsevier Science Inc
dc.publisherNew York
dc.publisherEUA
dc.relationTransplantation Proceedings
dc.relationTransplant. Proc.
dc.rightsfechado
dc.rightshttp://www.elsevier.com/about/open-access/open-access-policies/article-posting-policy
dc.sourceWeb of Science
dc.subjectMethylenetetrahydrofolate Reductase Gene
dc.subjectIntroduction Mass-spectrometry
dc.subjectTotal Homocysteine
dc.subjectGraft Recipients
dc.subjectPlasma
dc.subjectQuantitation
dc.subjectGenotypes
dc.subjectCysteine
dc.subjectDisease
dc.subjectTrap
dc.titleHyperhomocysteinemia and MTHFR C677T and A1298C polymorphisms are associated with chronic allograft nephropathy in renal transplant recipients
dc.typeArtículos de revistas


Este ítem pertenece a la siguiente institución